Fig. 3From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective reviewKaplan–Meier survival analysis for all-cause mortality. The prognosis of patients with immune-related adverse events (irAEs) was significantly better than that of patients without irAEs (P < 0.001). This was also detected in patients with a cardiovascular history (P < 0.001) and in those without a cardiovascular history (P < 0.001)Back to article page